At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 200 target
Drug / intervention
Tislelizumab (BGB-A317)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Multi-Center, Open-Label, Phase 2 Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Tislelizumab (BGB-A317) for MSI-H/dMMR Solid Tumors. Currently recruiting, targeting 200 participants across 29 sites.
Detailed Summary
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMSI-H/dMMR Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
201920202021202220232024202520262027
Enrollment StartSep 2018
First PostedNov 2018
TodayJul 2026
Primary CompletionNov 2026
Study CompletionSep 2027
First PostedNov 9, 2018
Enrollment StartSep 19, 2018
Primary CompletionNov 1, 2026
Study CompletionSep 1, 2027
TodayJul 1, 2026
Enrollment to primary: 8.1 yearsPosted 7.6 years agoPrimary completion in 4 months
Interventions
Tislelizumab (BGB-A317)drug
Anti-PD-1 Antibody